VERA
NASDAQVera Therapeutics Inc.
News · 26 weeks55+43%
2026-03-012026-08-23
Mix2190d
- Other7(33%)
- Insider7(33%)
- SEC Filings5(24%)
- Leadership2(10%)
Latest news
25 items- INSIDERAmendment: PRESIDENT AND CEO Fordyce Marshall exercised 46,250 shares at a strike of $2.90 and sold $1,956,187 worth of shares (46,250 units at $42.30) as part of a pre-agreed trading plan (SEC Form 4)4/A - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERAmendment: PRESIDENT AND CEO Fordyce Marshall exercised 18,500 shares at a strike of $2.90 and sold $701,769 worth of shares (18,500 units at $37.93) as part of a pre-agreed trading plan (SEC Form 4)4/A - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERAmendment: PRESIDENT AND CEO Fordyce Marshall exercised 18,500 shares at a strike of $2.90 and sold $679,747 worth of shares (18,500 units at $36.74) as part of a pre-agreed trading plan (SEC Form 4)4/A - Vera Therapeutics, Inc. (0001831828) (Issuer)
- SECSEC Form 10-Q filed by Vera Therapeutics Inc.10-Q - Vera Therapeutics, Inc. (0001831828) (Filer)
- SECVera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- PRVera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial ResultsTRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adults with IgAN; results expected in Q3 2026.Anticipated supplemental Biologics License Application (sBLA) submission to the FDA – expected in Q4 2026. BRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today reported its business highlights and financial results for the quarter ended June 30, 2026. "The accelerated approval and
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 63,011 shares of Class A common stock and restricted stock units (RSUs) underlying 44,987 shares of Class A common stock to Nancy Bowman, M.D., Ph.D., Vera’s new Chief Regulatory Officer, under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan), and on August 4, 2026, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purch
- SECSEC Form SCHEDULE 13G filed by Vera Therapeutics Inc.SCHEDULE 13G - Vera Therapeutics, Inc. (0001831828) (Subject)
- INSIDERChief Regulatory Officer Boman Nancy Lee was granted 44,987 shares (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 3 filed by new insider Boman Nancy Lee3 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 32,100 shares of Class A common stock and restricted stock units (RSUs) underlying 16,050 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock
- INSIDERPRESIDENT AND CEO Fordyce Marshall sold $1,956,187 worth of shares (46,250 units at $42.30) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 151,994 units (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- SECVera Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- PRVera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William TurnerBRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position. William Turner, current Chief Regulatory Officer of Vera Therapeutics, is planning to retire and transition to the role of Strategic Advisor in the third quarter of this year after a successful tenure at the company, including the recent accelerated approval of Vera Therapeutics’ first therapy in IgA nephropathy (IgAN), TRUTAKNA™ (atacicept-vymj). Nancy Boman, M.D., Ph.D., will succeed Mr. Turner as Chief Regulatory Officer of Vera Therapeutics. "On behalf of the Board of Director
- FDAFDA Approval for TRUTAKNA issued to VERA THERAPEUTICS INC.Submission status for VERA THERAPEUTICS INC.'s drug TRUTAKNA (ORIG-1) with active ingredient ATACIEPT-VYMJ has changed to 'Approval' on 07/07/2026. Application Category: BLA, Application Number: 761486, Application Classification:
- SECVera Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- PRVera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA NephropathyTRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN).1,2The TRUTAKNA dose is 150 mg injected subcutaneously once weekly, self-administered via an autoinjector by patients at home.1 Investor webcast is scheduled for July 7 at 4:30 pm EDT. A Media Snippet accompanying this announcement is available by clicking on this link. BRISBANE, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has gr
- INSIDERPRESIDENT AND CEO Fordyce Marshall sold $701,769 worth of shares (18,500 units at $37.93) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 198,244 units (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 28,800 shares of Class A common stock and restricted stock units (RSUs) underlying 14,150 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stoc
- SECVera Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- PRVera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA NephropathyPrescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR analysis now planned for Q3 2026, pulled forward from 2027Pending positive eGFR analysis, plans to submit a supplemental Biologics License Application (sBLA) in Q4 2026, with potential full approval in 2027 BRISBANE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced it has aligned with the U.S. Food and Drug
- SECVera Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- INSIDERSEC Form 4 filed by Director Morrison Scott W4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 4 filed by Director Cheng Andrew4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 4 filed by Director Seidenberg Beth C4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
VERA FAQ
7 questionsWhat does Vera Therapeutics Inc. do?
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco...Where does VERA stock trade?
Vera Therapeutics Inc. (VERA) is listed on NASDAQ.What sector and industry is VERA in?
Vera Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Vera Therapeutics Inc. go public?
Vera Therapeutics Inc. (VERA) completed its IPO in 2021.What are analysts saying about VERA?
Vera Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-03-11. Recent price targets range from $4800.00 to $4900.00.What companies are similar to VERA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VERA side-by-side with any of them on Quantisnow.How can I track VERA on Quantisnow?
Quantisnow aggregates Vera Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VERA to receive live email and push alerts on every new disclosure.